- Home
- NRO vs ACHV Comparison
NRO vs ACHV Comparison
Compare NRO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- ACHV
- Stock Information
- Founded
- NRO 2003
- ACHV N/A
- Country
- NRO United States
- ACHV Canada
- Employees
- NRO N/A
- ACHV N/A
- Industry
- NRO Finance/Investors Services
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NRO Finance
- ACHV Health Care
- Exchange
- NRO Nasdaq
- ACHV Nasdaq
- Market Cap
- NRO 189.8M
- ACHV 159.0M
- IPO Year
- NRO N/A
- ACHV N/A
- Fundamental
- Price
- NRO $4.03
- ACHV $4.52
- Analyst Decision
- NRO
- ACHV Strong Buy
- Analyst Count
- NRO 0
- ACHV 3
- Target Price
- NRO N/A
- ACHV $14.00
- AVG Volume (30 Days)
- NRO 239.4K
- ACHV 87.9K
- Earning Date
- NRO 01-01-0001
- ACHV 11-07-2024
- Dividend Yield
- NRO 11.41%
- ACHV N/A
- EPS Growth
- NRO N/A
- ACHV N/A
- EPS
- NRO N/A
- ACHV N/A
- Revenue
- NRO N/A
- ACHV N/A
- Revenue This Year
- NRO N/A
- ACHV N/A
- Revenue Next Year
- NRO N/A
- ACHV N/A
- P/E Ratio
- NRO N/A
- ACHV N/A
- Revenue Growth
- NRO N/A
- ACHV N/A
- 52 Week Low
- NRO $2.51
- ACHV $3.03
- 52 Week High
- NRO $3.45
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- NRO 75.35
- ACHV 50.71
- Support Level
- NRO $3.80
- ACHV $4.23
- Resistance Level
- NRO $4.03
- ACHV $4.33
- Average True Range (ATR)
- NRO 0.05
- ACHV 0.15
- MACD
- NRO 0.00
- ACHV 0.02
- Stochastic Oscillator
- NRO 95.65
- ACHV 53.13
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.